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Abstract
Limited evidence is available for relapsed small-cell lung cancer (SCLC). Five hundred eighty consecutive
patients with relapsed SCLC treated at our institute were analyzed. Multivariate analysis identiﬁed sensitive
relapse and amrubicin treatment as independent favorable prognostic factors for survival. Amrubicin showed a
favorable trend compared with cisplatin/etoposide/irinotecan in terms of the progression-free survival and
feasibility in SCLC patients with relapsed disease.
Background: Although several agents have been introduced for the treatment of relapsed small-cell lung cancer
(SCLC), there is still only limited evidence regarding second- and later-line chemotherapies for these patients. Pa-
tients and Methods: Consecutive patients with relapsed SCLC treated at the National Cancer Center Hospital be-
tween 2000 and 2014 were analyzed. Patients’ characteristics and treatments to explore factors associated with the
survival outcomes were reviewed. Results: A total of 580 patients diagnosed as having SCLC received ﬁrst-line
chemotherapy/chemoradiotherapy, of which 343 (59%) received second-line chemotherapy. Among the 343 pa-
tients, 193, 148, and 2 patients were diagnosed sensitive relapse, refractory relapse, and relapse of unknown
sensitivity status, respectively. Second-line chemotherapy regimens used were as follows: amrubicin (AMR) in 188
(55%) patients; weekly cisplatin/etoposide/irinotecan (PEI) in 56 (16%) patients; topotecan in 18 (5.2%) patients;
others in 81 (24%) patients. In the analysis including all patients, the following outcomes were obtained for the patients
treated with AMR and PEI, respectively: objective response rate: 51% and 73%; median progression-free survival: 4.5
and 4.2 months; median overall survival: 10.0 and 10.8 months. Multivariate analysis identiﬁed sensitive relapse to
ﬁrst-line treatment (vs. refractory relapse) (P ¼ .007) and AMR as second-line treatment (vs. PEI) (P ¼ .005) as in-
dependent favorable prognostic factors for survival. Conclusion: AMR showed a favorable trend compared with PEI in
terms of the progression-free survival and feasibility in SCLC patients with relapsed disease. Based on our ﬁndings,
we suggest that a randomized trial comparing AMR and PEI is warranted.
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Lung cancer is the most common cause of cancer death world-
wide.1 Small-cell lung cancer (SCLC) accounts for 15% to 18% of
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irinotecan, with a reported 2-year survival of approximately 40% in
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Second-Line AMR or PEI for Relapsed SCLCextensive disease.5-8 Despite their relatively good response to
chemotherapy and radiotherapy, the majority of patients with
SCLC eventually show disease progression. Therefore, second-line
therapy is often required, but the prognosis at relapse is still very
poor.9 Response to second-line chemotherapy is reportedly corre-
lated with the response to ﬁrst-line therapy, the interval between the
completion of initial chemotherapy, and the diagnosis of disease
progression.10 Patients who respond to ﬁrst-line chemotherapy and
show a progression-free interval of over 90 days are most often
regarded as showing sensitive relapse, as opposed to those showing a
progression-free interval of less than 90 days, who are labeled as
having refractory relapse.11-13
The importance of second-line therapy for SCLC was ﬁrst proven
by the pivotal phase III trial comparing best supportive care and
topotecan.14 Up until today, many studies of second-line treatment
have been conducted.12,13,15,16 In patients with sensitive relapse, the
reported overall response rate (ORR) is in the range of 22% to 24%,
and the reported median overall survival (OS) is in the range of 5 to
9 months12,13,15,16; on the other hand, in those with refractory
relapse, the reported ORR is in the range of 6% to 12%, and the
reported median OS is in the range of 3 to 5 months.11,14,16,17
Topotecan is still recognized as the standard choice worldwide for
relapsed SCLC, but its survival beneﬁt is limited. Amrubicin (AMR)
is a third-generation anthracycline and potent topoisomerase II in-
hibitor that received approval in Japan in 2002, and whose efﬁcacy
as monotherapy has been shown in several phase II trials.18-22 These
trials showed an ORR in the range of 36% to 53%, and a median
OS in the range of 6 to 14 months. However, randomized phase III
trials conducted in Western countries have failed to show its su-
periority over topotecan.16 Therefore, the use of AMR is limited
throughout the world. Recently, the efﬁcacy of a combination
regimen consisting of weekly cisplatin plus etoposide plus irinotecan
(PEI) has been demonstrated in patients with relapsed SCLC. In a
randomized controlled trial, the median OS was 18.2 months and
the ORR was 84%, both superior to those for topotecan.23 From
the many randomized trials conducted for relapsed SCLC, topo-
isomerase (TOPO) inhibitors appear to be the key drugs for treating
SCLC24; however, the choice of the best regimen needs further
study.
The objective of the present study was to retrospectively analyze
the outcomes of the second-line treatments employed for relapsed
SCLC over a 14-year period at our institution. In our analysis, AMR
was compared with PEI, because PEI is another choice of second-
line regimen alongside topotecan monotherapy after it showed its
efﬁcacy in a phase III trial, and no comparison of AMR and PEI has
been conducted yet.
Patients and Methods
Data Acquisition
Data of consecutive patients with SCLC receiving chemotherapy
at the National Cancer Center Hospital between 2000 and 2014
were analyzed. The patients’ clinical characteristics and treatments
were collected from the medical records.
Extracted clinical data included the demographic characteristics
(gender, age, date of diagnosis, and smoking history), known
baseline prognostic factors (Eastern Cooperative Oncology Group
performance status [PS], stage), ﬁrst- and second-line treatmentnical Lung Cancer Month 2016details (regimen, start, and last day of administration), and clinical
outcomes (response to treatment documented by each physician,
date of relapse, and date of last follow-up or death). Patients who
showed disease progression or relapsed within 90 days of completion
of the ﬁrst-line treatment were classiﬁed as having refractory relapse,
whereas the remainder were classiﬁed as having sensitive relapse.
AMR was administered at the dose of 40 mg/m2 for 3 consec-
utive days, every 21 days, and PEI consisted of cisplatin (25 mg/m2)
weekly for 10 weeks, etoposide (60 mg/m2) for 3 days on weeks 1,
3, 5, 7, and 9, and irinotecan (90 mg/m2) on weeks 2, 4, 6, 8, and
10, with granulocyte colony-stimulating factor support.
This retrospective study was conducted with the approval of the
Ethics Committee of the National Cancer Hospital (#2014-178),
and in accordance with the Declaration of Helsinki.
Statistical Analysis
Response rate was measured by each attending physician based
on radiographic images or clinical symptoms using the Response
Evaluation Criteria In Solid Tumors (RECIST) guideline (version
depending on the year of treatment).25 OS was calculated from date
of initiation of the second-line therapy to the date of death. The
progression-free survival (PFS) was calculated from the date of
initiation of the second-line therapy to the date of ﬁrst radiographic
or clinical documentation of progression or death. The Kaplan-
Meier point-estimate survival analysis was used to evaluate the
median PFS and OS. Log-rank statistics was used to compare the
survival between groups. A Cox proportional hazards regression
model was applied using variables thought to potentially inﬂuence
the survival: gender, age, PS, smoking history, disease stage, ﬁrst-
line treatment, and second-line treatment. All analyses were per-
formed using STATA, version 11 (StataCorp, College Station, TX).
Results
Patient Characteristics and Treatment Outcomes
Between 2000 and 2014, 580 patients with SCLC received ﬁrst-
line chemotherapy or chemoradiotherapy. Among the 512 patients
that developed relapse, 343 (59%) received second-line chemo-
therapy. Of the patients administered receiving second-line
chemotherapy, 193 (56%) were diagnosed as having sensitive
relapse and 148 (43%) as having refractory relapse. The selection of
chemotherapy was left to the discretion of the attending physician.
AMR was used most frequently in both groups, followed by PEI,
and then irinotecan monotherapy. Of the patients, 31% received
third-line treatment, and 11% received fourth- or later lines of
treatment. Figure 1 shows the patient ﬂow chart. The baseline
characteristics of the patients who received AMR and PEI are shown
in Table 1.
The median duration of chemotherapy was 4 cycles and 6 weeks
for AMR and PEI, respectively. The objective response rates (ORR)
were 51% and 73%, respectively (Table 2). The median PFS was
4.5 months (95% conﬁdence interval [CI], 4.1-5.2 months) in the
AMR group and 4.2 months (95% CI, 3.6-4.9 months) in the PEI
group (hazard ratio [HR], 1.40; 95% CI, 1.03-1.90) (Figure 2).
The median OS was 10.0 months (95% CI, 8.6-11.7 months) in
the AMR group and 10.8 months (95% CI, 8.0-13.8 months) in
the PEI group (HR, 1.13; 95% CI, 0.82-1.56) (Figure 3). When
the patients with sensitive relapse and refractory relapse were
Figure 1 Patient Flow Diagram
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6.4 months) in the sensitive relapse group treated with AMR, and
4.9 months (95% CI, 3.9-5.6 months) in the sensitive relapse group
treated with PEI (HR, 1.40; 95% CI, 0.91-2.14) (See Supplemental
Figure 1A in the online version). On the other hand, the median
PFS was 4.1 months (95% CI, 3.0-4.6 months) in the refractory
relapse group treated with AMR and 3.7 months (95% CI, 3.0-4.6
months) in the refractory relapse group treated with PEI (HR, 1.47;
95% CI, 0.92-2.34) (See Supplemental Figure 1B in the online
version). The median OS was 14.2 months (95% CI, 9.8-15.7
months) in the sensitive relapse group treated with AMR and 14.8
months (95% CI, 10.2-17.9 months) in the sensitive relapse group
treated with PEI group (HR, 0.96; 95% CI, 0.61-1.53) (See
Supplemental Figure 2A in the online version). On the other hand,
the median OS was 8.0 months (95% CI, 6.4-9.4 months) in the
refractory relapse group treated with AMR and 8.0 months (95%
CI, 4.5-11.1 months) in the refractory relapse group treated with
PEI (HR, 1.31; 95% CI, 0.83-2.04) (See Supplemental Figure 2B
in the online version).
Prognostic Factor Analysis
Multivariate Cox regression analysis of the data from all 244
patients administered second-line AMR or PEI identiﬁed sensi-
tivity to ﬁrst-line chemotherapy (sensitive relapse over refractory
relapse) and second-line chemotherapy regimen used (AMR over
PEI) as independent predictors of the PFS (Table 3). The same
analysis revealed sensitivity to ﬁrst-line chemotherapy (sensitive
relapse over refractory relapse) and age (younger than 66 years over
66 years and older) as additional signiﬁcant factors. We conductedthe same analysis after dividing the patients into sensitive- and
refractory relapse groups. Of the 128 patients of the sensitive
relapse group that received second-line AMR or PEI, PS (0-1 over
2-3) and second-line chemotherapy (AMR over PEI) were iden-
tiﬁed as independent predictors of the PFS following ﬁrst-line
treatment (See Supplemental Table 1 in the online version). No
signiﬁcant predictive factor for OS was identiﬁed. On the other
hand, in the 116 patients of refractory relapse treated with AMR
or PEI, no signiﬁcant prognostic factors were identiﬁed, although
second-line treatment (See Supplemental Table 2 in the online
version) was associated with a HR of 1.48 (95% CI, 0.84-2.62)
favoring AMR.
Discussion
In a large cohort of SCLC patients treated for disease relapse, we
found that AMR and PEI were the most frequently used second-line
therapies. Both treatments yielded survival outcomes worthy of
notice, with a more favorable trend in the AMR-treated patients.
Multivariate analysis identiﬁed second-line treatment with AMR as
an independent favorable prognostic factor in terms of the PFS.
This tendency was also seen in the patient group with sensitive
relapse. Furthermore, in the refractory relapse group as well, a more
favorable trend for the PFS was observed in the AMR as compared
with the PEI treatment group. The median OS in the AMR
treatment group was striking, in that it was substantially longer than
that reported from phase III trials conducted abroad, where AMR is
not considered as a second-line therapy because it failed to show a
survival advantage in a randomized phase III trial, and also showed
more toxicity.16Clinical Lung Cancer Month 2016 - 3
Table 1 Patient Demographic and Clinical Characteristics
AMR (n [ 188) PEI (n [ 56) Others (n [ 99)
n % n % n %
Gender
Female 45 24 9 16 18 18
Male 143 76 47 84 81 82
Age, years
Median (range) 65 (24-81) 66 (45-78) 68 (29-86)
Performance status
0 60 32 23 41 32 32
1 103 55 30 54 55 56
2 16 8.5 3 5.4 8 8
3 7 3.7 0 0 4 4
Unavailable 2 1.1 0 0 0 0
Smoking history
Never-smoker 8 4.3 3 5.4 6 6
Smoker 179 95 53 95 93 94
Unavailable 1 0.5 0 0 0 0
Stage
LD 51 27 16 29 66 67
ED 134 71 38 68 33 33
Unavailable 3 1.6 2 3.6 0 0
First-line treatment
Platinum þ ETP  RT 94 50 33 59 58 59
Platinum þ IRI  RT 69 37 14 25 14 14
Platinum þ IRI þ ETP  RT 25 13 4 23 8 8
Others 0 0 5 8.9 35 35
Relapse
Sensitive 99 53 29 52 65 66
Refractory 89 47 27 48 32 32
Unavailable 0 0 0 0 2 2
Abbreviations: AMR ¼ Amrubicin; ED ¼ extensive disease; ETP ¼ etoposide; IRI ¼ irinotecan; LD ¼ limited disease; PEI ¼ weekly cisplatin/etoposide/irinotecan; RT ¼ radiotherapy.
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4 - CliAMR is the world’s ﬁrst anthracycline anti-cancer agent produced
entirely through chemical synthesis26; it was ﬁrst synthesized with
the intent of developing an anti-tumor agent stronger thanTable 2 Overall Response Rate
AMR (n [ 188)
All
Sensitive
Relapse (n [ 99)
Refractory
(n [
Median cycles/week (range) 4 (1-27) 4 (1-27) 4 (1-
Response, n
CR 7 5 2
PR 88 51 37
SD 57 30 28
PD 28 8 19
Unavailable 8 5 3
Objective response rate, % 51 57 44
Disease control rate, % 81 87 75
Abbreviations: AMR ¼ Amrubicin; CR ¼ complete response; PD ¼ progressive disease; PEI ¼ we
nical Lung Cancer Month 2016doxorubicin (DXR). The active metabolite amrubicinol plays an
important role in the antitumor effect of this drug, and the major
mechanism of action of AMR is the stabilization of a cleavablePEI (n [ 56)
Relapse
89) All
Sensitive Relapse
(n [ 29)
Refractory Relapse
(n [ 27)
17) 6 (1-10) 6 (1-10) 6 (1-10)
4 3 1
37 20 17
9 4 5
5 2 3
0 0 1
73 79 67
89 93 85
ekly cisplatin/etoposide/irinotecan; PR ¼ partial response; SD ¼ stable disease.
Figure 2 Progression-Free Survival of Patients Treated With
AMR and PEI (n [ 244)
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4.45 (95% CI, 4.12 to 5.24)
4.18 (95% CI, 3.62 to 4.88)
(HR =  1.40; (95% CI, 1.03 to 1.90)
No. at risk
AMR 188 63 17 9 4 4 3 3 3 1 1
PEI 56 11 3 2 1 1 1 1 1 1 1
Abbreviations: AMR ¼ Amrubicin; HR ¼ hazard ratio; PEI ¼ weekly cisplatin/etoposide/
irinotecan.
Table 3 Multivariate Cox Regression Analysis of PFS in
Patients Treated With AMR and PEI (n [ 244)
Factor No. HR 95% CI P
Gender 0.56-1.13 .20
Female 54 1
Male 190 0.79
Age 0.75-1.39 .92
65 years 130 1
>65 years 114 1.02
ECOG PS 0.82-2.36 .22
0-1 196 1
2-3 26 1.39
Smoking history 0.77-3.83 .19
Never-smoker 11 1
Smoker 232 1.72
Stage 0.81-1.76 .37
LD 67 1
ED 172 1.19
First-line treatment 0.73-1.46 .86
ETP 127 1
IRI 83 1.03
Sensitivity to ﬁrst-line 1.13-2.18 .007
Sensitive-relapse 128 1
Refractory-relapse 116 1.57
Second-line treatment 1.16-2.34 .005
AMR 188 1
PEI 56 1.65
Abbreviations: AMR ¼ Amrubicin; CI ¼ conﬁdence interval; ECOG ¼ Eastern Cooperative
Oncology Group; ED ¼ extended disease; ETP ¼ etoposide; HR ¼ hazard ratio;
IRI ¼ irinotecan; LD ¼ limited disease; PEI ¼ weekly cisplatin/etoposide/irinotecan;
PFS ¼ progression-free survival; PS ¼ performance status.
Hitomi Sumiyoshi Okuma et alcomplex within the cancer cells via DNA topoisomerase II (Topo
II). In studies using human tumor xenografts, AMR was demon-
strated to exert a stronger antitumor effect than DXR against breast
cancer (xenograft MX-1), small cell lung cancer (xenograft LX-1),
and gastric cancer (xenografts SC-6, SC-9, and 4-1ST). In vivo
research has demonstrated that AMR causes stronger myelosup-
pression than DXR, but that, however, recovery from the myelo-
suppressive effect of AMR is more rapid than that from the
myelosuppressive effect of DXR.27 Cardiotoxicity is rarely
encountered as compared with that for other anthracycline agents,
and cumulative toxicities, such as renal failure associated with
platinum agents, is not a concern. Therefore, AMR is a more
feasible treatment option, in that it exerts less toxicity and requires
fewer days of hospitalization. These ﬁndings suggest that AMR is a
treatment that can be used for a long time without any substantiveFigure 3 Overall Survival of Patients Treated With AMR and PEI
(n [ 244)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
O
ve
ra
ll 
S
ur
vi
va
l (
pr
ob
ab
ili
ty
)
0 6 12 18 24 30 36 42 48 54 60
Time from second-line treatment (months)
AMR
PEI
Median, months
9.95 (95% CI, 8.63 to 11.7)
10.8 (95% CI, 8.01 to 13.8)
(HR =  1.13; (95% CI, 0.82 to 1.56)
No. at risk
AMR 188 127 63 35 21 15 10 5 4 1 1
PEI 56 41 23 13 6 4 3 2 2 1 1
Abbreviations: AMR ¼ Amrubicin; HR ¼ hazard ratio; PEI ¼ weekly cisplatin/etoposide/
irinotecan.concern about cumulative toxicities, as compared with combination
therapies based on platinum agents; therefore, AMR is one of the
useful drugs that should be considered in the course of treatment in
patients with SCLC.
Patients with SCLC with sensitive relapse showed a better
sensitivity to second-line treatment and a better prognosis as
compared with those with refractory relapse. The ORR of 55%
and median PFS of 5.3 months in the sensitive relapse group
treated with AMR in the present study are similar to the outcomes
reported from a phase II trial of an ORR of 67%, median PFS of
5.4 months, and median OS of 14.4 months in patients with
SCLC with sensitive relapse assigned to the AMR treatment
arm.28 In the phase III Amrubicin Clinical Trial-1 (ACT-1) trial,
the ORR was 40.9%, the median PFS was 5.5 months, and the
median OS was 9.2 months in the sensitive relapse subgroup of
patients with SCLC treated with AMR.16 In the patients with
SCLC with sensitive relapse treated with PEI in the present study,
the ORR was 87% and the median PFS was 4.9 months. Ac-
cording to another randomized phase III trial of PEI in the second-
line setting for patients with SCLC with sensitive relapse, the ORR
was 84%, the median PFS was 5.7 months, and the median OS
was 18.2 months.23 Interestingly, among the patients with sensi-
tive relapse in the present study, a better survival was obtained inClinical Lung Cancer Month 2016 - 5
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6 - Clithe AMR treatment group as compared with the PEI treatment
group. With the present data and the historical trial of PEI
showing a survival beneﬁt over topotecan, we believe that the true
beneﬁt of AMR will become manifest in properly selected patients,
for example, those with sensitive relapse.
From the aspect of toxicity, there was 1 treatment-related death
(1.8%) in the PEI treatment group and 2 treatment-related deaths
(1.0%) in the AMR treatment group in this study. Historical data
showed a higher adverse event occurrence rate in the PEI treatment
group; the grade 3 to 4 adverse events in the PEI treatment group
were neutropenia (83.3%), anemia (84.4%), thrombocytopenia
(41.1%), diarrhea (7.8%), and febrile neutropenia (FN; 31.1%).23
On the other hand, the grade 3 to 4 adverse events in the AMR
treatment group were neutropenia (41%), thrombocytopenia
(21%), anemia (16%), infections (16%), febrile neutropenia (10%),
and cardiac disorders (5%).16 Myelosuppression is critical, because
refractory patients already have depressed bone marrow function.
The 3-drug combination of PEI was originally designed as a weekly
regimen to make it easier to modify the dosage and schedule.29,30
However, the frequency of febrile neutropenia of 31.1% despite
granulocyte colony-stimulating factor support is high for patients
receiving second-line treatment and is 2- to 3-fold higher as
compared with that reported for monotherapy regimens. Further-
more, patients scheduled to receive PEI treatment need to be hos-
pitalized, whereas AMR treatment can be administered on an
outpatient basis. Therefore, AMR monotherapy is more feasible and
is also associated with lower toxicity.
The results also revealed exceptionally long-term survivors in the
AMR treatment group. One of these patients received 27 cycles of
treatment, and 6 received 16 to 18 cycles. Based on a study of long-
term survival in 1714 consecutive SCLC patients, Lassen et al re-
ported a 5-year survival rate of 3.5%31; they reported ED, PS > 2,
presence of liver and/or bone marrow metastases, and elevated
lactate dehydrogenase and/or alkaline phosphatase levels as negative
prognostic factors. In our patient cohort, 6 patients (2.5%) survived
for longer than 5 years, and indeed, all 6 patients had limited disease
and a PS of 0 to 1. In addition, 5 of the patients received AMR as
the second-line treatment, with 3 patients still, at the time of
writing, under AMR treatment. AMR is a drug that could be
administered over the long term, provided it shows efﬁcacy, as it has
very low toxicity.
Some of the limitations of this study were that the database was
from a single institute, and the study was retrospective in nature; the
number of patients in the PEI arm was small; treatment was selected
according to the physicians’ discretion and may have, therefore,
been biased. Also, both treatment groups include patients treated in
practice and those enrolled in an ongoing clinical trial at the time.
Therefore, some patients’ tumor response evaluations were made by
the treating physician, whereas others were evaluated according to
each trial protocol, which may have contributed to the longer PFS
compared with a cohort from a pure clinical trial. Furthermore, our
results showed substantially longer median overall survival times as
compared with reports from previous phase III trials of AMR or
topotecan carried out abroad, which could be related to possible
differences in the genetic background, medical care, study design,
and/or drug exposure,32 and the higher frequency of use ofnical Lung Cancer Month 2016post-relapse treatments including AMR, irinotecan, and topotecan
in Japan. The similar median overall survival between AMR and
PEI in our analysis may possibly have been due to post-relapse
treatment or other factors; nonetheless, the long survival and
simplicity of the regimen compared with PEI should be valued.
Conclusion
Our results revealed that relapsed patients with SCLC receiving
AMR as second-line therapy showed a longer median PFS as
compared to those receiving PEI, with a similar median OS between
the 2 treatment groups. A longer median PFS with AMR was also
conﬁrmed in patients diagnosed as having sensitive relapse. The 2
treatment groups showed different feasibility proﬁles. AMR is a
highly active and well-tolerated treatment option that deserves to be
recognized as a second-line treatment of choice as compared with
topotecan and PEI, on the basis of the better survival and shorter
hospitalization, respectively. Further investigation comparing AMR
and PEI in selected patient groups is necessary.
Clinical Practice Points
 Despite their relatively good response to chemotherapy and
radiotherapy, the majority of patients with SCLC eventually
show disease progression.
 The importance of second-line therapy for SCLC was ﬁrst
proven by the pivotal phase III trial comparing best supportive
care and topotecan. Later, many studies of second-line treatment
have been conducted, including AMR monotherapy and a
combination regimen consisting of PEI.
 Both regimens have shown a survival beneﬁt over topotecan in
randomized trials in Japan. However, AMR failed to show its
superiority over topotecan in a phase III trial; therefore, it is not a
widely used drug around the world.
 The choice of the best regimen needs further study. No study has
investigated the efﬁcacy comparing AMR and PEI.
 In our analysis, AMR and PEI were the most used regiments at
our institute.
 The following outcomes were obtained for AMR and PEI,
respectively: ORR: 51% and 73%; median PFS: 4.5 and 4.2
months; and median OS: 10.0 and 10.8 months. Multivariate
analysis identiﬁed sensitive relapse to ﬁrst-line treatment (vs.
refractory relapse) (P ¼ .007) and AMR as second-line treatment
(vs. PEI) (P ¼ .005) as independent favorable prognostic factors
for survival. AMR showed a more favorable outcome in terms of
the feasibility and survival. Exceptionally long-term survivors
were observed in patients treated with AMR.
 Based on our ﬁndings, we suggest that a randomized trial
comparing AMR and PEI is warranted.Acknowledgments
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Supplemental Figure 1 Progression-Free Survival of Sensitive-Relapse (n [ 128) (A) and Refractory-Relapse (n [ 116) (B)
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Abbreviations: AMR ¼ Amrubicin; HR ¼ hazard ratio; PEI ¼ weekly cisplatin/etoposide/irinotecan.
Supplemental Figure 2 Overall Survival of Sensitive-Relapse (n [ 128) (A) and Refractory-Relapse (n [ 116) (B)
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Supplemental Table 1 Multivariate Cox Regression Analysis
of PFS in Patients With Sensitive
Relapse (n [ 128)
Factor No. HR 95% CI P
Gender 0.51-1.34 .44
Female 30 1
Male 98 0.82
Age 0.44-1.08 .11
65 years 66 1
>65 years 62 0.67
ECOG PS 1.03-5.87 .04
0-1 99 1
2-3 7 2.46
Smoking history 0.85-7.51 .09
Never-smoker 5 1
Smoker 122 2.53
Stage 0.84-2.37 .19
LD 53 1
ED 74 1.41
First-line treatment 0.77-2.17 .33
ETP 63 1
IRI 47 1.30
Second-line treatment 1.09-2.80 .02
AMR 99 1
PEI 29 1.74
Abbreviations: AMR ¼ Amrubicin; CI ¼ conﬁdence interval; ECOG ¼ Eastern Cooperative
Oncology Group; ED ¼ extended disease; ETP ¼ etoposide; HR ¼ hazard ratio; IRI ¼ irino-
tecan; LD ¼ limited disease; PEI ¼ weekly cisplatin/etoposide/irinotecan; PFS ¼ progression-
free survival; PS ¼ performance status.
Supplemental Table 2 Multivariate Cox Regression Analysis
of PFS in Patients With Refractory
Relapse (n [ 116)
Factor No. HR 95% CI P
Gender 0.35-1.13 .12
Female 24 1
Male 92 0.62
Age 0.81-2.07 .27
65 years 64 1
>65 years 52 1.30
ECOG PS 0.27-1.13 .10
0-1 97 1
2-3 19 0.56
Smoking history 0.26-2.41 .68
Never-smoker 6 1
Smoker 110 0.79
Stage 0.64-2.40 .53
LD 14 1
ED 98 1.24
First-line treatment 0.46-1.27 .30
ETP 64 1
IRI 36 0.76
Second-line treatment 0.84-2.62 .14
AMR 89 1
PEI 27 1.48
Abbreviations: AMR ¼ Amrubicin; CI ¼ conﬁdence interval; ECOG ¼ Eastern Cooperative
Oncology Group; ED ¼ extended disease; ETP ¼ etoposide; HR ¼ hazard ratio; IRI ¼ irino-
tecan; LD ¼ limited disease; PEI ¼ weekly cisplatin/etoposide/irinotecan; PFS ¼ progression-
free survival; PS ¼ performance status.
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